News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Regeneron Pharmaceuticals, Inc. (REGN) Named World's #1 Biopharmaceutical Employer in Science Magazine Annual Survey


9/24/2012 12:02:34 PM

TARRYTOWN, N.Y., Sept. 21, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that Science magazine has ranked Regeneron as the #1 employer in the global biopharmaceutical industry in the journal's annual Top Employers Survey.

"This recognition by Science as the most respected company to work for in the biopharmaceutical industry is very satisfying for all of us at Regeneron," said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron Pharmaceuticals and George D. Yancopoulos, M.D., Ph.D., Chief Scientific Officer and President, Regeneron Laboratories. "Since we opened our first lab in 1989, we have believed that innovative science could be harnessed to deliver important new medicines for serious conditions. As we have grown from a handful of people to nearly 1,900 employees today, we have worked hard to maintain a culture that values rigorous science, creative thinking, and collegiality. We are fortunate to have such talented employees who are dedicated to discovering and developing new treatments for patients in need."

This is the first year that Regeneron has captured the #1 position and the first time a New York based company has topped the survey. Last year Regeneron was ranked #2.

The 2012 survey sought to identify the companies with the best reputations as employers, based on 4,276 survey responses from readers of Science and other survey invitees. Survey participants came from North America (78%), Europe (14%), and Asia/Pacific Rim (5%); 93% worked in private industry. Details of the rankings and survey results can be found in the September 21 online edition of Science and will be featured in the October 19, 2012 print issue.

On Monday, September 24, New York State Lt. Governor Robert Duffy and U.S. Congresswoman Nita Lowey and other public officials are scheduled to participate in an event with Regeneron's Tarrytown employees that will recognize this important achievement.

Separately, Regeneron announced another step to reinforce its commitment to science by launching a new Post-Doctoral Training Program that is accepting applications for its 2013 class. The three-year multi-faceted program will integrate cutting edge science with didactic training, discussion groups, and focused mentoring.

About Regeneron Pharmaceuticals, Inc.
Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets three products in the United States, EYLEA® (aflibercept) Injection, ZALTRAP® (ziv-aflibercept) Injection for Intravenous Infusion, and ARCALYST® (rilonacept) Injection for Subcutaneous Use; ZALTRAP is co-commercialized with Sanofi. Regeneron has filed a regulatory application with the U.S. Food and Drug Administration (FDA) for a second indication for EYLEA. Phase 3 studies are in progress with EYLEA in two additional indications and with product candidates sarilumab and REGN727. Regeneron has active research and development programs in many disease areas, including ophthalmology, inflammation, cancer, and hypercholesterolemia. Additional information and recent news releases are available on the Regeneron web site at www.regeneron.com.

Contact Information:
Peter Dworkin
Corporate Communications
914.847.7640
peter.dworkin@regeneron.com

Manisha Narasimhan, Ph.D.
Investor Relations
914.847.5126
manisha.narasimhan@regeneron.com

SOURCE Regeneron Pharmaceuticals, Inc.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES